S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$962.49
-3.81 (-0.39%)
(As of 03/28/2024 ET)
Today's Range
$959.25
$970.79
50-Day Range
$930.00
$993.35
52-Week Range
$684.80
$998.33
Volume
461,802 shs
Average Volume
442,739 shs
Market Capitalization
$105.64 billion
P/E Ratio
27.70
Dividend Yield
N/A
Price Target
$967.59

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
0.5% Upside
$967.59 Price Target
Short Interest
Healthy
1.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.33mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$13.12 M Sold Last Quarter
Proj. Earnings Growth
4.11%
From $38.18 to $39.75 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

235th out of 938 stocks

Pharmaceutical Preparations Industry

105th out of 441 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
REGN Apr 2024 1040.000 call
REGN Mar 2024 995.000 call
REGN Nov 2024 1050.000 call
REGN Nov 2024 620.000 put
REGN Dec 2025 750.000 call
REGN Jan 2026 750.000 call
REGN Mar 2024 885.000 put
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/02/2024
Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$967.59
High Stock Price Target
$1,184.00
Low Stock Price Target
$680.00
Potential Upside/Downside
+0.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
19 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
32.01%

Debt

Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$43.22 per share
Book Value
$236.63 per share

Miscellaneous

Free Float
100,070,000
Market Cap
$105.64 billion
Optionable
Optionable
Beta
0.11

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals has a strong product portfolio including EYLEA injection for various eye conditions and Dupixent injection for atopic dermatitis and asthma, which have shown significant market success.
  • The company's recent development of REGEN-COV for covid-19 has positioned it well in the fight against the pandemic, potentially leading to increased revenue and market share.
  • Regeneron Pharmaceuticals has a solid financial standing with a market capitalization of $106.06 billion, indicating stability and growth potential.
  • The company's consistent investment in research and development for various diseases showcases a commitment to innovation and future growth opportunities.
  • Regeneron Pharmaceuticals' stock price has shown positive performance, with a current trading price of $966.30, reflecting investor confidence and potential for capital appreciation.

Cons

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Regeneron Pharmaceuticals operates in a highly competitive industry with constant regulatory challenges and pricing pressures, which could impact profitability and market share.
  • The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of any unforeseen issues with these products.
  • Regeneron Pharmaceuticals' PEG ratio of 2.76 indicates that the stock may be overvalued compared to its growth prospects, potentially leading to limited upside for investors.
  • The company's debt-to-equity ratio of 0.10 suggests a moderate level of debt, which could increase financial risk, especially in times of economic uncertainty or market downturns.
  • Regeneron Pharmaceuticals' beta of 0.11 indicates low volatility compared to the market, which may result in slower price movements and potentially lower returns for investors seeking higher-risk investments.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, March 27, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

19 Wall Street research analysts have issued 12 month target prices for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $680.00 to $1,184.00. On average, they predict the company's share price to reach $967.59 in the next twelve months. This suggests a possible upside of 0.5% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 on January 1st, 2024. Since then, REGN shares have increased by 9.6% and is now trading at $962.49.
View the best growth stocks for 2024 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast
.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) posted its earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company earned $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 17.61% and a net margin of 30.14%. The firm's revenue was up .6% compared to the same quarter last year. During the same period last year, the firm posted $10.96 earnings per share.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.11%), Vanguard Group Inc. (8.05%), Capital World Investors (4.71%), Capital International Investors (2.68%), Dodge & Cox (2.16%) and Putnam Investments LLC (1.11%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners